Immunophenotypic Markers and Antiretroviral Therapy (IMART)

T cell activation and maturation help predict treatment response

Donna Mildvan, Ronald J. Bosch, Ryung S. Kim, John Spritzler, David W. Haas, Daniel Kuritzkes, Jonathan Kagan, Mostafa Nokta, Victor DeGruttola, Melanie Moreno, Alan Landay

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4+ and CD8+ T cells in 324 subjects. Regression models - adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study - revealed that high pretreatment CD8+ T cell activation predicted virologic failure (P = .046). Additional models showed the greatest increase in CD4+ T cell counts in subjects with highest pretreatment naive CD4+ T cell counts (P<.0001), which was enhanced by high CD4+ and low CD8+ T cell activation. Total lymphocyte count also predicted a subsequent CD4 + T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)1811-1820
Number of pages10
JournalJournal of Infectious Diseases
Volume189
Issue number10
DOIs
StatePublished - May 15 2004
Externally publishedYes

Fingerprint

T-Lymphocytes
CD4 Lymphocyte Count
Therapeutics
Information Dissemination
Lymphocyte Count
Virus Diseases
HIV-1
Acquired Immunodeficiency Syndrome
Clinical Trials
HIV
RNA

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Immunophenotypic Markers and Antiretroviral Therapy (IMART) : T cell activation and maturation help predict treatment response. / Mildvan, Donna; Bosch, Ronald J.; Kim, Ryung S.; Spritzler, John; Haas, David W.; Kuritzkes, Daniel; Kagan, Jonathan; Nokta, Mostafa; DeGruttola, Victor; Moreno, Melanie; Landay, Alan.

In: Journal of Infectious Diseases, Vol. 189, No. 10, 15.05.2004, p. 1811-1820.

Research output: Contribution to journalArticle

Mildvan, D, Bosch, RJ, Kim, RS, Spritzler, J, Haas, DW, Kuritzkes, D, Kagan, J, Nokta, M, DeGruttola, V, Moreno, M & Landay, A 2004, 'Immunophenotypic Markers and Antiretroviral Therapy (IMART): T cell activation and maturation help predict treatment response', Journal of Infectious Diseases, vol. 189, no. 10, pp. 1811-1820. https://doi.org/10.1086/383277
Mildvan, Donna ; Bosch, Ronald J. ; Kim, Ryung S. ; Spritzler, John ; Haas, David W. ; Kuritzkes, Daniel ; Kagan, Jonathan ; Nokta, Mostafa ; DeGruttola, Victor ; Moreno, Melanie ; Landay, Alan. / Immunophenotypic Markers and Antiretroviral Therapy (IMART) : T cell activation and maturation help predict treatment response. In: Journal of Infectious Diseases. 2004 ; Vol. 189, No. 10. pp. 1811-1820.
@article{7a9ffd1b55a14c2c982c04810db798ee,
title = "Immunophenotypic Markers and Antiretroviral Therapy (IMART): T cell activation and maturation help predict treatment response",
abstract = "To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4+ and CD8+ T cells in 324 subjects. Regression models - adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study - revealed that high pretreatment CD8+ T cell activation predicted virologic failure (P = .046). Additional models showed the greatest increase in CD4+ T cell counts in subjects with highest pretreatment naive CD4+ T cell counts (P<.0001), which was enhanced by high CD4+ and low CD8+ T cell activation. Total lymphocyte count also predicted a subsequent CD4 + T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection.",
author = "Donna Mildvan and Bosch, {Ronald J.} and Kim, {Ryung S.} and John Spritzler and Haas, {David W.} and Daniel Kuritzkes and Jonathan Kagan and Mostafa Nokta and Victor DeGruttola and Melanie Moreno and Alan Landay",
year = "2004",
month = "5",
day = "15",
doi = "10.1086/383277",
language = "English (US)",
volume = "189",
pages = "1811--1820",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Immunophenotypic Markers and Antiretroviral Therapy (IMART)

T2 - T cell activation and maturation help predict treatment response

AU - Mildvan, Donna

AU - Bosch, Ronald J.

AU - Kim, Ryung S.

AU - Spritzler, John

AU - Haas, David W.

AU - Kuritzkes, Daniel

AU - Kagan, Jonathan

AU - Nokta, Mostafa

AU - DeGruttola, Victor

AU - Moreno, Melanie

AU - Landay, Alan

PY - 2004/5/15

Y1 - 2004/5/15

N2 - To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4+ and CD8+ T cells in 324 subjects. Regression models - adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study - revealed that high pretreatment CD8+ T cell activation predicted virologic failure (P = .046). Additional models showed the greatest increase in CD4+ T cell counts in subjects with highest pretreatment naive CD4+ T cell counts (P<.0001), which was enhanced by high CD4+ and low CD8+ T cell activation. Total lymphocyte count also predicted a subsequent CD4 + T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection.

AB - To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4+ and CD8+ T cells in 324 subjects. Regression models - adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study - revealed that high pretreatment CD8+ T cell activation predicted virologic failure (P = .046). Additional models showed the greatest increase in CD4+ T cell counts in subjects with highest pretreatment naive CD4+ T cell counts (P<.0001), which was enhanced by high CD4+ and low CD8+ T cell activation. Total lymphocyte count also predicted a subsequent CD4 + T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection.

UR - http://www.scopus.com/inward/record.url?scp=2442655107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442655107&partnerID=8YFLogxK

U2 - 10.1086/383277

DO - 10.1086/383277

M3 - Article

VL - 189

SP - 1811

EP - 1820

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 10

ER -